Alkem Laboratories Limited Keeps 51% Stake in Saudi Arabia JV

Alkem Laboratories Limited will retain a 51% stake in its planned Saudi Arabian joint venture, while Vitals Biotech Company will hold the remaining 49% following an agreement amendment approved on February 13, 2026. The change preserves Alkem's majority ownership as it prepares to establish a pharmaceutical and nutraceutical business in the Kingdom of Saudi Arabia.

What changed in Alkem Laboratories Limited's Saudi Arabia joint venture?

Alkem Laboratories Limited approved an amendment under which Vitals Biotech Company, rather than Abdulaziz Alsheikh directly, will own the 49% minority stake in the proposed Saudi Arabian joint venture. Vitals Biotech Company is wholly owned by Alsheikh, who was named as the Saudi partner in the original shareholders' agreement.

The amendment does not alter Alkem's ownership or the intended business of the venture. Alkem will continue to hold 51% of the total share capital, retaining majority control in the proposed subsidiary. The planned entity is yet to be incorporated.

The Board of Directors approved the revised arrangement on February 13, 2026. The original shareholders' agreement, signed on August 12, 2025, had provided for Alsheikh to personally hold the 49% stake. The approved change shifts that holding to his wholly owned company.

Alkem disclosed the development under Regulation 30 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations. It also stated that the proposed transaction does not fall under related-party transaction requirements and that its promoter, promoter group and group companies have no interest in the entity.

Why is Alkem establishing a subsidiary in Saudi Arabia?

Alkem is establishing the subsidiary to expand its business and market reach in the Kingdom of Saudi Arabia. The proposed limited liability company will manufacture, import, market and distribute pharmaceutical and nutraceutical products within the country.

The Saudi venture was proposed as a strategic investment through cash consideration, with the amount to be determined at the time of incorporation. Alkem's filing did not disclose an investment value, projected revenue, production capacity or a specific incorporation date.

Under the original agreement, the subsidiary was proposed to be established within one year from the agreement's execution on August 12, 2025. That stated timeframe provides the disclosed schedule for completing incorporation, although the company has not announced that the legal entity has been formed.

The proposed operations cover both pharmaceuticals and nutraceuticals. This gives the venture a defined commercial scope across local manufacturing, imports, marketing and distribution, rather than limiting it to a single product or sales channel.

What are the key facts about Alkem's Saudi Arabia expansion?

The key facts are that Alkem retains a 51% majority stake, Vitals Biotech Company will hold 49%, and the venture remains proposed rather than incorporated. The ownership amendment changes the minority shareholder's holding vehicle but leaves the overall economic split unchanged.

Before the amendment, the 49% stake was to be held by Abdulaziz Alsheikh. After the amendment, that same stake will be held by Vitals Biotech Company, which is wholly owned by Alsheikh. Alkem's control position and the stated purpose of the joint venture remain the same.

Alkem already has overseas operating entities in Dubai, including Alkem Pharmaceuticals Scientific Office FZ-LLC and Alkem Pharma Trading FZCO. The proposed Saudi subsidiary represents a separate planned structure for operations within Saudi Arabia, with a local joint-venture ownership arrangement.

How does the planned venture matter to Alkem investors and operations?

The planned venture matters because it creates a framework for Alkem to operate in Saudi Arabia through a majority-owned local entity. The company has specified manufacturing, importing, marketing and distribution as the business lines, indicating that the proposed platform is intended to support more than product imports alone.

For investors, the disclosed information establishes ownership, partners, intended activities and an incorporation timeline, but it does not quantify the investment or its likely financial contribution. As a result, the immediate financial effect cannot be measured from the available disclosure.

The amendment also clarifies the legal holder of the minority stake. Since Vitals Biotech Company is wholly owned by the original Saudi partner, the change does not revise Alkem's 51% ownership, the 49% minority interest, or the stated strategic objective of expanding into Saudi Arabia.

Alkem's domestic sales were reported at Rs 2,265 crore for the referenced quarter, up 12% year on year, with India accounting for 68.3% of overall sales compared with 67.6% in the comparable prior-year period. These figures underline the continued importance of the Indian market while the company pursues the disclosed Saudi expansion plan.

Conclusion

Alkem's February 2026 approval maintains the structure of its Saudi Arabian expansion: the company will own 51% of the proposed subsidiary and Vitals Biotech Company will own 49%. The amendment changes the minority shareholder from the individual Saudi partner to his wholly owned company, without changing the venture's planned activities or Alkem's control.

The next disclosed milestone is incorporation of the subsidiary, which was proposed within one year of the August 12, 2025 shareholders' agreement. Investors can watch for updates on incorporation, the cash consideration determined at that stage, and further details on the venture's operating plans.